Midas
Equities and Research

# Blue Jet Healthcare Ltd

## Q2FY27 Result Update

06 Nov 2026

- ✓ Revenue grew 127% Y-o-Y, beating our estimate by 4.6%, supported by the PI/API ramp-up and higher Contrast Media sales.
- ✗ EBITDA margin contracted 186 bps Q-o-Q to 31.6%, missing our estimate by 40 bps, as disruptions in West Asia led to higher input costs.
- ✓ PI/API revenue surged 322% Y-o-Y to Rs. 183 CR, driven by existing programmes and newer commercial products.

| Rating | 1Y Target Price | CMP |
|---|---|---|
| BUY<br>Maintained | Rs. 696<br>Revised Upward (+2%) | Rs. 576<br>1Y Upside: ~21% \| 24.9x FY28E P/E |

**Estimate Update:** FY27E Revenue Rs. 1,337 cr (+2.7%) | FY27E PAT Rs. 366 cr (+2.3%) | FY28E Revenue Rs. 1,579 cr (+2.6%) | FY28E PAT Rs.438 cr (+2.6%) | Midas valuation multiple maintained at 30x FY28E P/E.


**RESEARCH ANALYST**
**Viswanath AVR**
viswanath.avr@sparkcapital.in
**Samar Gupta**
Samar.g@sparkcapital.in

# Spark Result Update Reports – Rebooted!

## Outlining the framework from our desk

In our new, rejuvenated approach to publishing fundamental research ideas, we aim to balance a traditional, time-tested framework with a contemporary and, hopefully, refreshing approach to stock-picking. Accordingly, our Result Update reports will be presented in four sections: **(1) Business Assessment Scores, (2) Valuation Framework, (3) Decision Tree, and (4) Stock Buzz & Influencing Factors.**

This report is underpinned by three key beliefs: (1) business assessment should be separated from valuation frameworks, allowing equity research to objectively calibrate the mix when making stock calls; (2) the decision tree we publish makes this process simple and objective, highlighting the three major factors that underpin our recommendation; and (3) reactions to "buzz" and other factors that influence price action must be identified and given due regard when timing stock calls, particularly in the current environment, where information flow is incessant.

### Business Assessment Scores

To assess whether a company's business can emerge as a long-term winner, we draw on Porter's Five Forces framework to examine key aspects such as revenue models, pricing risks, market positioning, and competitive moats. Our financial analysis and estimates are anchored in our assessment of both the company's current performance and its long-term potential. To ensure that this assessment remains objective and is not influenced by subjective judgment, we employ a scoring model that captures the key drivers of business quality across five composite vectors. The resulting scores form the basis of our call on the business.

### Valuation Framework

We have often observed how markets can make target multiples seem to emerge like the proverbial rabbits out of a hat. To avoid the temptation of retrospectively justifying valuations in line with the broader market, we returned to first principles while designing our Valuation Framework. Anchored in market, peer, and historical absolute benchmarks, our valuation scores incorporate Economic Value Added, return profiles, growth prospects, and leadership positions, mapped against relevant valuation multiples. Ultimately, the central question remains: given everything we know about the business, markets, and peers, does the current pricing appear attractive? This question forms the bedrock of stock-picking in equity research.

### Stock Buzz & Influencing Factors

The Buzz Chart & Liquidity Chart track stock-specific news flow, events, and market activity to help identify periods of elevated attention or sentiment shifts, complementing fundamental and valuation analysis.

### Decision tree

A schematic view of what we hinge our stock recommendation on. In our opinion, a discerning investor can identify the essence of our pitch from a limited, yet reasonably exhaustive, set of factors that can be organized as branches of a tree. The decision tree we publish makes this process simple and objective, highlighting the three major factors that underpin our recommendation.

*Source: Company, and Midas Research*

# Q2FY27 Results Summary

*(In Rs. cr)*

| Particulars | Q2FY26 | Q1FY27 | Q2FY27 | Y-o-Y | Q-o-Q | vs Midas estimate | Var |
|---|---|---|---|---|---|---|---|
| **Net Sales** | **165** | **293** | **376** | 127% | 28% | **359** | **4.6%** |
| COGS | (58) | (137) | (193) | 234% | 41% | | |
| Gross Profit | 108 | 156 | 182 | 70% | 17% | | |
| ***Gross Margin*** | ***65.0%*** | ***53.2%*** | ***48.5%*** | ***-1649bps*** | ***-468bps*** | | |
| Employee cost | (19) | (20) | (20) | | | | |
| *% of revenue* | *-11.2%* | *-6.9%* | *-5.4%* | | | | |
| Other expenses | (34) | (38) | (43) | | | | |
| *% of revenue* | *-20.6%* | *-12.9%* | *-11.5%* | | | | |
| **EBITDA** | **55** | **98** | **119** | 116% | 21% | **115** | 3.3% |
| ***EBITDA Margin*** | ***33.2%*** | ***33.5%*** | ***31.6%*** | ***-160bps*** | ***-186bps*** | ***32.0%*** | ***-40bps*** |
| Depreciation | (6) | (7) | (7) | | | | |
| *% of revenue* | *-3.5%* | *-2.3%* | *-1.8%* | | | | |
| **EBIT** | **49** | **91** | **112** | 128% | 22% | | |
| ***EBIT Margin*** | ***29.7%*** | ***31.2%*** | ***29.8%*** | ***10bps*** | ***-141bps*** | | |
| Other Income | 24 | 15 | 26 | | | | |
| *% of revenue* | *14.7%* | *5.2%* | *7.0%* | | | | |
| Interest | (5) | (1) | (1) | | | | |
| *% of revenue* | *-2.8%* | *-0.2%* | *-0.2%* | | | | |
| **PBT** | **69** | **106** | **137** | 100% | 30% | | |
| ***PBT Margin*** | ***41.5%*** | ***36.1%*** | ***36.6%*** | ***-497bps*** | ***42bps*** | | |
| Tax | (17) | (28) | (35) | | | | |
| *Tax Rate* | *-24.1%* | *-26.1%* | *-25.4%* | | | | |
| **Profit After Tax** | **52** | **78** | **103** | 96.6% | 31% | **98** | 4.7% |
| ***PAT Margin*** | ***31.5%*** | ***26.7%*** | ***27.3%*** | ***-422bps*** | ***58bps*** | ***27.3%*** | **2bps** |
| **EPS** | **3.01** | **4.51** | **5.46** | 81% | 21% | **5.2** | 5.5% |
| **Adj EPS** | **3.02** | **4.51** | **5.42** | 80% | 20% | **5.2** | 4.7% |

**Revenue Y-o-Y**
**127%**
Growth led by PI/API ramp-up and higher Contrast Media sales.

**EBITDA Y-o-Y**
**116%**
Higher input costs compressed margins despite strong growth.

**EBITDA Margins**
**31.6%**

**PAT Y-o-Y**
**97%**

**PAT Margin**
**27.3%**

**Revenue vs Est.**
**+4.6%**
Aided by strong demand from existing programmes & newer product contributions

*Source: Company, and* Midas Research

Midas
Equities and Research

# Q2FY27 Conference Call – Key Takeaways

## Business performance & order visibility

- Blue Jet reported record quarterly revenue of Rs. 376 cr (+127% Y-o-Y; +28% Q-o-Q), exceeding our estimate by 4.6% and marking its fourth consecutive quarter of sequential growth. H1FY27 revenue increased 28.6% Y-o-Y to Rs. 669 cr.
- PI/API revenue stood at Rs. 183 cr (up 322.4% Y-o-Y; 51.5% Q-o-Q), aided by existing programmes and newer products. Management confirmed commercial supplies of oncology and CNS products, with commercialised products contributing the bulk of PI/API revenue. Individual molecule contributions were not disclosed.
- Contrast Media revenue increased to Rs. 145 cr (up 79.7% Y-o-Y; 25.1% Q-o-Q). Management described production volumes as broadly steady Q-o-Q and did not quantify the contribution from the recognition of Q1 goods-in-transit. Regarding longer-term performance, management cited volume growth, some volume discounts and varying product realisations.
- Sweetener revenue declined to Rs. 28 cr (down 18.5% Y-o-Y; 30.2% Q-o-Q). The proposed Vizag sweetener is different from the existing portfolio and is backed by firm commitments from existing customers, although its identity was not disclosed.
- Management highlighted healthy order visibility across PI/API and Contrast Media but declined to provide a sustainable quarterly revenue run rate or fixed sequential growth guidance.

## Profitability, input costs & cash conversion

- EBITDA surged 116% Y-o-Y & 21% Q-o-Q to Rs. 119 cr, beating our estimate by 3.3%. EBITDA margin contracted 160 bps Y-o-Y & 186 bps Q-o-Q to 31.6%, 40 bps below our estimate.
- Gross margin contracted to 48.5%, from 65.0% in Q2FY26 and 53.2% in Q1FY27. Management attributed pressure to higher raw-material, reagent, solvent, and catalyst costs following West Asia disruptions, with the timing of purchases and inventory consumption influencing when inflation affects margins.
- Certain customer price hikes take effect from Q3FY27. Management expects a positive margin impact, although reagent and solvent inflation cannot be fully passed through. Recovery remains dependent on input prices, product mix, and contractual adjustments; no firm margin floor was provided.
- PAT increased 96.6% Y-o-Y and 31% Q-o-Q to Rs. 103 cr, exceeding our estimate by 4.7%. H1FY27 EBITDA and PAT stood at ~Rs. 217 cr and Rs. 181 cr, respectively.
- H1FY27 operating cash flow turned negative at Rs. 25.6 cr vs. positive Rs. 207.2 cr a year earlier. Working capital absorbed ~Rs. 210.9 cr, including Rs. 96.5 cr through receivables and Rs. 63.9 cr via inventory. Cash expenditure on property, plant, equipment & intangible assets was Rs. 76.1 cr.

## Capacity expansion, R&D & funding

- Mahad's contrast-media KSM backward-integration facility remains targeted for commissioning in H2FY27, with ~Rs. 250 cr incurred so far, supporting cost competitiveness and supply security.
- Vizag Units V and VI span ~100 acres, with Phase I capex of ~Rs. 1,000 cr allocated across contrast media, pharma intermediates, sweeteners, peptide fragments and multipurpose blocks. Key environmental approvals are in place, and pre-construction activities are underway.
- Major lateral-transfer volumes are contingent on Vizag commissioning, with potential interim supplies from existing facilities. CDMO & contrast media remain the larger investment priorities.
- Hyderabad R&D is operational, supporting capabilities in flow synthesis, peptide/GLP-related intermediates, biocatalysis, high-potency products and solid-phase chemistry.
- The Rs. 800 cr QIP, raised at Rs. 506 per share through the issuance of ~1.58 cr shares, will be deployed over three years towards capex, working capital and general corporate purposes.
- Management indicated that renewable energy now accounts for approximately 80% of overall energy consumption.

## New products & development pipeline

- A new contrast-media intermediate was delivered and validated for an innovator. The underlying molecule remains in late-stage clinical development; its revenue contribution and commercial ramp-up schedule were not disclosed.
- Management expects further forward integration in contrast media to improve realisations and margins but did not quantify the potential uplift or confirm the shipment status of the separately discussed iodinated intermediate.
- Amino-acid derivatives for peptide fragments have been developed, with shipments indicated for Q4FY27. The underlying innovator programme remains in clinical development, and supplies to date were trial/validation quantities.
- Blue Jet's current peptide strategy focuses on building blocks and fragments, with further integration dependent on customer requirements. Management did not provide peptide-specific margins or asset-turnover guidance and cautioned against extrapolating historical asset turns to future investments.

*Source: Company, Spark PWM Pvt. Ltd.*

# Blue jet Healthcare Ltd – Q2FY27 Result Update


CMP ~Rs. 576

Rating BUY


## Blue jet Healthcare - Our Commentary On Results

- Blue Jet reported record Q2FY27 revenue of Rs. 376 cr, up 127% Y-o-Y and 28% Q-o-Q, beating our estimate by 4.6%. Growth was driven by existing programmes and newer products in PI/API, with revenue rising 322% Y-o-Y to Rs. 183 cr. Contrast Media revenue grew 80% Y-o-Y to Rs. 145 cr, while Sweetener revenue declined 19% to Rs. 28 cr.
- EBITDA grew 116% Y-o-Y to Rs. 119 cr, exceeding our estimate by 3.3%. However, higher input costs compressed EBITDA margin by 160 bps Y-o-Y to 31.6%, 40 bps below our estimate. Price increases for certain customers will take effect from Q3FY27. PAT rose 96.6% Y-o-Y to Rs. 103 cr, beating our estimate by 4.7%, with higher other income supporting sequential growth.
- Hyderabad R&D became operational, while Mahad commissioning remains targeted for H2FY27. The Rs. 800 cr QIP will support expansion, although H1 operating cash outflow of Rs. 25.6 cr highlights working-capital pressure. Management indicated healthy order visibility but cautioned against extrapolating Q2 revenue.

## Business Assessment Scores




## Valuation Framework




## Financials and Estimates Summary

| Particulars (Rs. cr) | Revenue | EBITDA | EBITDA % | PAT | EPS | RoE % | RoCE % | PE | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| FY24 | 712 | 229 | 32.2% | 171 | 9.9 | 21.5% | 30.1% | 58.5 | 46.9 |
| FY25 | 1,030 | 378 | 36.7% | 305 | 17.6 | 30.8% | 41.1% | 32.8 | 28.5 |
| FY26 | 947 | 294 | 31.0% | 248 | 14.3 | 19.9% | 27.2% | 40.3 | 36.6 |
| FY27E | 1,337 | 434 | 32.5% | 366 | 19.8 | 18.9% | 25.5% | 29.2 | 24.8 |
| FY28E | 1,579 | 537 | 34.0% | 438 | 23.1 | 16.1% | 21.7% | 24.9 | 20.0 |

*Source: Company reports, Bloomberg, Midas Research*
Note: There is a change in number of shares post the QIP that took place in July 2026

**06 Nov 2026**

| | |
|---|---|
| Industry | Pharmaceuticals |

### Key Stock Data

| | |
|---|---|
| Bloomberg | BLUEJET IN |
| Shares o/s (cr) | 18.9 |
| Market Cap (Rs. cr) | 10,909 |
| 52-wk High/Low | 648/325 |
| 20M ADV (In '000) | 272.1 |
| Index | SMLCAP |
| F&O | N |

### Latest Shareholding (%)

| | Sep 26 | Jun 26 | Mar 26 |
|---|---|---|---|
| Promoters | 73.1 | 79.8 | 79.8 |
| Institutions | 8.3 | 5.1 | 5.4 |
| Public | 18.6 | 15.1 | 14.8 |
| Pledge | 0.0 | 0.0 | 0.0 |

### Stock Performance (%)

| | 1M | 3M | 12M |
|---|---|---|---|
| BLUEJET IN | 3.4 | (2.4) | (5.0) |
| Nifty 500 | 5.7 | (2.1) | (1.2) |



**RESEARCH ANALYST**
**Viswanath AVR**
viswanath.avr@sparkcapital.in
**Samar Gupta**
Samar.g@sparkcapital.in


Midas Equities and Research

# Decision Tree – Stock call

CMP ~Rs. 576

Rating BUY




## 1 Reasoning 1

- PI/API and Contrast Media Performance: PI/API revenues recorded exceptional growth in Q2FY27, surging 322.1% Y-o-Y, driven by business normalisation and strong momentum. The Contrast Media segment also continued to deliver robust growth, with revenue rising 79.6% Y-o-Y.
- Growth drivers: Earnings growth will be driven by higher volumes from expanding CMI sales, sustained momentum in the PI/API portfolio, commercialisation of new molecules & CDMO opportunities from Vizag.
- We therefore expect revenue to grow at a robust CAGR of 29.1% over FY26–FY28E.

## 2 Reasoning 2

- Cost pressures & pass-through: Although the company is expected to pass on higher raw material costs to customers, the anticipated 1–2-quarter lag in pass-through is likely to result in a slight downward revision to near-term EBITDA margin estimates.
- Long-term structural benefits: Backward integration at Mahad strengthens Blue Jet's cost competitiveness by internalising key CMI intermediates, reducing import dependence and improving supply-chain reliability.
- Margin trajectory: Operating leverage from revenue growth & a higher contribution from differentiated PI/API products will boost medium-term profitability, with EBITDA margins likely to expand to ~34% by FY28.

## 3 Reasoning 3

- Platform Evolution: Blue Jet is evolving into a broader specialty CDMO/API platform, supported by investments in contrast media, high-intensity sweeteners, advanced chemistry capabilities, and its newly operational Hyderabad R&D facility.
- Robust earnings growth visibility, led by its differentiated niche portfolio & long-term supply agreements.
- The stock trades at ~25x FY28E P/E. We assign a target multiple of 30x FY28E P/E, implying a PEG ratio of ~0.9x, reflecting the company's superior earnings growth prospects and improving business quality.

*Source: Company, and* Midas Research

Midas Equities and Research

# Change in Estimates

**Context:** Earnings estimates have been revised upwards following better-than-expected Q2FY27 performance and improved execution, primarily in the Pharma Intermediates (PI/API) segment.

| | New estimates | | Old estimates | | Change | |
|---|---|---|---|---|---|---|
| **Description** | **FY27E** | **FY28E** | **FY27E** | **FY28E** | **FY27E** | **FY28E** |
| **Net Sales (Rs. cr)** | 1,337 | 1,579 | 1,302 | 1,539 | 2.7% | 2.6% |
| **EBITDA (Rs. cr)** | 434 | 537 | 430 | 523 | 1.1% | 2.6% |
| **EBITDA Margin** | 32.5% | 34.0% | 33.0% | 34.0% | -50bps | 0bps |
| **Adj PAT (Rs. cr)** | 366 | 438 | 357 | 427 | 2.3% | 2.6% |
| **PAT Margin** | 27.3% | 27.7% | 27.5% | 27.7% | -11bps | 0bps |
| **EPS (Rs.) *** | 19.8 | 23.1 | 19.3 | 22.5 | 2.3% | 2.6% |

**Estimates revision:** Following the strong Q2FY27 performance, we have revised our revenue estimates upwards by 2.7% for FY27E and 2.6% for FY28E, driven primarily by the normalisation of the Pharma Intermediates (PI/API) business and continued growth in the Contrast Media segment. However, we have marginally trimmed our EBITDA margin estimates (by ~50 bps for FY27E) to account for higher raw material costs. While the company is expected to pass on these cost increases to customers, the anticipated pass-through lag of 1–2 quarters is likely to weigh on near-term margins. Our revisions remain measured, given the inherently lumpy nature of the PI/API business, where quarterly performance can vary meaningfully and should not be extrapolated on an annualised basis.

**Valuation Summary**


| Target Multiple | Target EPS | 1Y TP | PEG Ratio | 1Y Upside (Incl. Dividends) |
|---|---|---|---|---|
| **30x FY28E P/E** | **Rs. 23.1** | **Rs. 696** | **~0.9x** | **21%** |
| Maintained | FY28E EPS | Incl. dividends | Attractive vs peers | From CMP |

*Source: Company, and* Midas Research
Note: Old estimates have been adjusted for the new number of shares post the QIP

Midas Equities and Research

# Stock Buzz & Influencing Factors

## Follow the money




*Source: Company, Midas Research, Bloomberg*

Midas
Equities and Research

# Financial Summary

All figures in Rs. cr

| Particulars | FY24 | FY25 | FY26 | FY27E | FY28E |
|---|---|---|---|---|---|
| **Profit & Loss** | | | | | |
| Revenue | 712 | 1,030 | 947 | 1,337 | 1,579 |
| Gross profit | 397 | 569 | 512 | 695 | 852 |
| EBITDA | 229 | 378 | 294 | 434 | 537 |
| Depreciation | (28) | (18) | (24) | (27) | (37) |
| EBIT | 201 | 360 | 270 | 407 | 500 |
| Other Income | 29 | 46 | 69 | 86 | 90 |
| Interest expense | (0) | (0) | (6) | (6) | (6) |
| Exceptional items | (10) | - | - | - | - |
| PBT | 220 | 406 | 333 | 487 | 584 |
| Reported PAT (after Non-Controlling Interests) | 164 | 305 | 248 | 366 | 438 |
| Adj PAT | 171 | 305 | 248 | 366 | 438 |
| EPS (Rs.) | 9.9 | 17.6 | 14.3 | 19.8 | 23.1 |
| **Balance Sheet** | | | | | |
| Net Worth | 845 | 1,133 | 1,360 | 2,505 | 2,920 |
| Total debt | - | - | - | - | - |
| Non-Controlling Interests | - | - | - | - | - |
| Other liabilities and provisions | 10 | 33 | 58 | 58 | 58 |
| **Total Net worth and liabilities** | 855 | 1,166 | 1,418 | 2,563 | 2,978 |
| Gross Fixed assets | 249 | 378 | 395 | 595 | 745 |
| Net fixed assets | 149 | 260 | 253 | 426 | 539 |
| Capital work-in-progress | 147 | 89 | 301 | 550 | 850 |
| Intangible Assets | - | - | - | - | - |
| Investments | 250 | 187 | 252 | 252 | 252 |
| Cash and bank balances | 85 | 120 | 149 | 758 | 670 |
| Loans & advances and other assets | 23 | 40 | 61 | 61 | 61 |
| Net working capital | 201 | 470 | 402 | 516 | 606 |
| **Total assets** | 855 | 1,166 | 1,418 | 2,563 | 2,978 |
| Capital Employed | 845 | 1,133 | 1,360 | 2,505 | 2,920 |
| Invested Capital (CE - cash - CWIP) | 613 | 924 | 910 | 1,197 | 1,400 |
| Net debt | (85) | (120) | (149) | (758) | (670) |
| **Cash Flows** | | | | | |
| Cash flows from Operations (Pre-tax) | 252 | 135 | 443 | 320 | 447 |
| Cash flows from Operations (post-tax) | 241 | 46 | 334 | 199 | 301 |
| Capex | (174) | (79) | (219) | (449) | (450) |
| Free cashflows | 68 | (34) | 115 | (250) | (149) |
| Free cashflows (post interest costs) | 67 | (34) | 108 | (256) | (155) |
| Cash flows from Investing | (264) | (35) | (276) | (362) | (360) |
| Cash flows from Financing | (2) | (19) | (31) | 773 | (28) |
| **Total cash & liquid investments** | **85** | **120** | **149** | **758** | **670** |

| Particulars | FY24 | FY25 | FY26 | FY27E | FY28E |
|---|---|---|---|---|---|
| **Growth ratios (%)** | | | | | |
| Revenue | -1.3% | 44.7% | -8.0% | 41.1% | 18.1% |
| EBITDA | 4.6% | 64.8% | -22.1% | 47.7% | 23.5% |
| Adj PAT | 6.9% | 78.4% | -18.8% | 47.5% | 19.7% |
| **Margin ratios** | | | | | |
| Gross | 55.8% | 55.2% | 54.0% | 52.0% | 54.0% |
| EBITDA | 32.2% | 36.7% | 31.0% | 32.5% | 34.0% |
| Adj PAT | 24.0% | 29.6% | 26.2% | 27.3% | 27.7% |
| **Performance ratios** | | | | | |
| Pre-tax OCF/EBITDA | 110.1% | 35.7% | 150.6% | 73.7% | 83.3% |
| OCF/IC (%) | 39.3% | 5.0% | 36.7% | 16.6% | 21.5% |
| RoE (%) | 21.5% | 30.8% | 19.9% | 18.9% | 16.1% |
| RoCE (%) | 30.1% | 41.1% | 27.2% | 25.5% | 21.7% |
| Fixed asset turnover (x) | 2.9 | 2.7 | 2.4 | 2.2 | 2.1 |
| Total asset turnover (x) | 0.9 | 1.0 | 0.7 | 0.7 | 0.6 |
| **Financial stability ratios** | | | | | |
| Net Debt to Equity (x) | (0.1) | (0.1) | (0.1) | (0.3) | (0.2) |
| Net Debt to EBITDA (x) | (0.4) | (0.3) | (0.5) | (1.7) | (1.2) |
| Interest cover (x) | 1,249 | 3,672 | 43 | 65 | 80 |
| Working capital days | 103 | 167 | 155 | 141 | 140 |
| **Valuation metrics** | | | | | |
| Fully Diluted Shares (cr) | 17.3 | 17.4 | 17.3 | 18.5 | 18.9 |
| Market cap (Rs. cr) | | | 10,909 | | |
| P/E (x) | 58.5 | 32.8 | 40.3 | 29.2 | 24.9 |
| P/OCF(x) | 45.2 | 238.4 | 32.6 | 54.9 | 36.2 |
| EV (Rs.cr) (ex-CWIP) | | | 10,760 | | |
| EV/ EBITDA (x) | 46.9 | 28.5 | 36.6 | 24.8 | 20.0 |
| EV/ OCF(x) | 44.6 | 235.1 | 32.2 | 54.2 | 35.7 |
| FCF Yield | 0.6% | -0.3% | 1.1% | -2.3% | -1.4% |
| Price to BV (x) | 12.9 | 9.6 | 8.0 | 4.4 | 3.7 |
| Dividend pay-out (%) | 11% | 7% | 8% | 6% | 5% |
| Dividend yield (%) | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% |
| Cash as a % of CE | 10.0% | 10.6% | 10.9% | 30.3% | 23.0% |

# Disclaimer (1/2)

## Absolute Rating Interpretation

| | | | |
|---|---|---|---|
| **BUY** | Stock expected to provide positive returns of >15% over a 1-year horizon | **REDUCE** | Stock expected to provide returns of <5% – -10% over a 1-year horizon |
| **ACCUMULATE** | Stock expected to provide positive returns of >5% – <15% over a 1-year horizon | **SELL** | Stock expected to fall >10% over a 1-year horizon |

The terms defined above are applicable to fundamental research reports published by the Research Analyst. For technical research reports, the expected (target) price is given in the report along with the time period within which it can be achieved. For Momentum Ideas the expected timeline to achieve the price target would be upto 3 months from the date of publication of the research report.

Spark PWM Private Limited **("Spark PWM")** holding SEBI Research Analyst Registration No.: INH200008954 and its affiliates are engaged in the business of investment banking, structured finance, asset management and private wealth management. Spark PWM is also registered with SEBI as a Stock Broker, Portfolio Manager, Depository Participant, Investment Adviser and is also a Mutual Fund Distributor registered with the Association of Mutual Funds in India (AMFI) and is also registered with Association of Portfolio Managers in India as a distributor of portfolio management products. Spark PWM is also Investment Manager to a Category I Alternative Investment Fund.

Spark PWM's affiliates include (1) Spark Capital Advisors (India) Private Limited which is registered with SEBI as Category I Merchant Banker, (2) Spark Asia Impact Private Limited (formerly known as Spark Alternative Asset Advisors India Private Limited) which is an investment manager to a Category II Alternative Investment Fund (3) Spark Asia Impact Managers Private Limited (formerly known as Spark Fund Managers Private Limited) which is registered with SEBI as a Portfolio Manager and (4) Spark Fund Advisors LLP which is an investment manager to a Category II and a Category III Alternative Investment Fund, (5) Spark Financial Holdings Private Limited and (6) Spark Global PWM Private Limited, a Category 4 DIFC registered company engaged in providing financial services.

The information and opinion expressed in this research report do not constitute an offer or an invitation to make an offer, to buy or sell any securities. The securities quoted in this document are for illustration only and are not recommendatory. This research report is provided by Spark PWM on a strictly confidential basis for the exclusive use of the recipient and has been obtained from published information and other sources, which Spark PWM or its affiliates consider to be reliable. None of the research analysts of Spark PWM accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this research report.

This research report does not claim to contain all information that an investor / potential investor may require for the purpose of making an investment. The past performance of a security, product or portfolio does not in any manner indicate the surety of performance in future. Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

This research report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Spark PWM also puts together Technical Analysis, and each recipient of this report must note that the views of the Technical Analyst is always based on short term market variables and will be materially different from the views of the other sector/fundamental analyst in Spark PWM, whose research reports are based on fundamental analysis of the subject company. Each recipient of this research report should make such assessment as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this research report (including the merits and risks involved) and should consult their own advisors. This research report is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. The price and value of the investments referred to in this research report and the income from them may go up or down, and investors may realize losses on their investments. Spark PWM does not provide tax advise to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment. The material is based on information that we consider reliable and may be obtained from third-parties or derived / deducted on the basis of such information. Spark PWM does not represent that such information is accurate or complete.

This research report is not directed or intended for distribution or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Spark PWM and/or its affiliates to obtain any registration or licensing requirement within such jurisdiction. The research analyst preparing this research report is not registered as a broker-dealer in the United States and, therefore, is not subject to US Rules regarding the preparation of research reports. The Research Analysts contributing to this report are residents outside the United States and are not associates, employees, registered or qualified as research analysts with FINRA or a US-regulated broker dealer. Recipients of this material should keep themselves informed about any such restrictions. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. This material should not be construed as an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction where such an offer or solicitation would be illegal. Recipients shall be solely liable for any liability incurred by them in this regard and will indemnify Spark PWM and/or its affiliates for any liability it may incur in this respect.

Securities markets may be subject to significantly higher risks, and in particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.By accepting this document, you agree to be bound by all the provisions as may be applicable pursuant to it. Nothing contained herein should be relied upon as a promise, representation or an indication of future performance. Certain statements made herein may not be based on historical information or facts and may appear to be "Forward Looking Statements", including those relating to general business plans, future financial condition and growth prospects. The actual results may differ materially from any "Forward-Looking statements" due to a number of factors, including socio, political, competitive environment, force majeure etc. Spark PWM makes no representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this research report.

While we would endeavour to update the information herein on a reasonable basis, Spark PWM is under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent Spark PWM from doing so. Neither Spark PWM nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for views or opinions expressed in this report or the contents or any errors or discrepancies herein or for any decisions or actions taken in reliance on the report or the inability to use or access our service in this report or for any loss or damages whether direct or indirect, incidental, special or consequential including without limitation loss of revenue or profits that may arise from or in connection with the use of or reliance on this report. Opinions expressed herein are our current opinion as of the date of appearing on this material only.

Spark PWM and/or its affiliates and/or employees may have interests/positions, financial or otherwise, in the securities mentioned in this report. To enhance transparency, Spark PWM has incorporated disclosure of interest statement in this research report. This should, however, not be treated as an endorsement of views expressed in this report.

Spark Capital Advisors (India) Private Limited (holding company of Spark PWM) has gone through a process of reorganisation and demerged its institutional equities business (stock broking license and research analyst license) to Spark Institutional Equities Private Limited (Resultant Company) through a Composite Scheme of Demerger ("Scheme"). Further the shares of SIE has been bought by Avendus Capital Private Limited with effect from December 20, 2022.

# Disclaimer (2/2)

## Disclosure of Interest & Material Conflict of Interest Statement

DISCLOSURE OF INTEREST

Name of the Research Analyst (s): Viswanath AVR and Samar Gupta

The research analyst(s) hereby certifies that opinion expressed in this research report accurately reflects his or her personal opinion about the subject securities and no part of his or her compensation was or will be directly or indirectly related to the specific recommendation and opinion expressed in this research report.

| Sr No. | Particulars | Yes/No |
|---|---|---|
| 1. | Research Analyst or his/her relative's has financial interest in the subject company(ies) | No |
| 2. | Research Analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the research report | No |
| 3. | Research Analyst or his/her relative has any other material conflict of interest at the time of publication of the research report | No |
| 4. | Research Analyst has served as an officer, director or employee of the subject company(ies) | No |
| 5. | Research Analyst has been engaged in market making activity for the subject company(ies) | No |

- Spark PWM may have financial interest in the subject company(ies).
- Spark PWM may have actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the research report.
- Spark PWM may have any other material conflict of interest at the time of publication of the research report.
- Spark PWM may have received any compensation from the subject company in the past twelve months.
- Spark PWM may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
- Spark PWM may have received any compensation or other benefits from the subject company or third party in connection with the research report.
- Spark PWM may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- Spark PWM may have been engaged in market making activity for the subject company(ies).

Since Spark PWM and its associates are engaged in various businesses in the financial services industry, they may have financial interest or may have received compensation for investment banking or merchant banking or brokerage services or for any other product or services of whatsoever nature from the subject company(ies) in the past twelve months or associates of Spark PWM may have managed or co-managed public offering of securities in the past twelve months of the subject company(ies) whose securities are discussed herein.

Associates of Spark PWM may have actual/beneficial ownership of 1% or more and/or other material conflict of interest in the securities discussed herein.

Spark PWM and/or its affiliates and/or employees, or their relative(s) may have a financial interest in the subject company. Spark PWM and/or its affiliates may have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report. Spark PWM and/or its associates and/or its employees have been engaged in market making activity for the subject company.

In the last twelve month period ending on the last day of the month immediately preceding the date of publication of the research report, Spark PWM and/or its affiliates and/or employees Research Analyst(s) may have;

- managed/co-managed public offering of securities for the subject company;
- received compensation for investment banking/merchant banking/brokerage services/other products/ services of the group from the subject company of this research report;
- received any compensation or other benefit from the subject company or third party in connection with the research report;
- provided services to the subject company as a client under the various services provided by Spark PWM or its affiliates.

However, the above shall have no bearing on the specific recommendation made by the research analyst(s), as the recommendation made by the research analyst(s) are independent of the view of the affiliates of Spark PWM. No part of the research analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this report.

Research reports are not exchange traded products, and hence disputes relating to research activities of Spark PWM do not have access to exchange investor redressal or arbitration mechanism. Spark PWM also hereby declares that its activities were neither suspended nor Spark PWM has defaulted with any Stock Exchange authority with whom Spark PWM is registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other competent authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

**Certification by Each of the Authors of the Report**

The research analyst certifies that the views expressed in this research report are a representation of the Analyst's personal opinions on the stock or sector as covered and reported. The Analyst is principally responsible for the preparation of this research report and does not have any material conflict of interest at the time of publication of this report.

A graph of the daily closing price of securities available is at https://economictimes.indiatimes.com/markets/stocks/stock-quotes (Choose a company from the list on the browser and select the "5 years" option from the drop-down available in the price chart).

Spark PWM Private Limited. (Registered Office: No. 1, 3rd Floor, First Crescent Park Road, Gandhi Nagar, Adyar, Chennai 600 020; CIN: U66190TN2012PTC086696; Telephone No.: +91 44 69250000; Website: www.sparkcapital.in; Correspondence Address: Solitaire Corporate Park, Unit 1252 , Building No. 12, Andheri Kurla Road, Chakala, Andheri (East), Mumbai 400093; Telephone No: +91 22 62916700; SEBI Registration: (Stock Broker: INZ000285135; Portfolio Manager: INP200007274; Research Analyst: INH200008954; BSE RA Enlistment No- 5503; Investment Adviser: INA000021067; BSE IA Enlistment No. 2390; Depository Participant: IN-DP-757-2023); AMFI – Registered Mutual Fund Distributor: ARN 86685. APMI – Registered PMS Distributor (APRN00662). Compliance and Grievance Officer details: Mr. Anupam Mohaney: +91 22 62916700. RA Grievance Redressal Matrix & Research T & C

**Spark PWM Private Limited does not use any Artificial Intelligence tools to provide research services.**

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

# Our Offices



### Chennai

No. 1, 3rd Floor,
First Crescent Park Road,
Gandhi Nagar,
Adyar,
Chennai – 600 020



### Mumbai

Unit – 301, 302, Windsor House,
2, Kolivery Village,
MMRDA Area, Kalina,
Santacruz East,
Mumbai – 400 098

11th floor, C Wing, ONE BKC,
Unit Nos. 1116,
Bandra Kurla Complex,
Bandra East,
Mumbai – 400 051



### Delhi

No. 23, 1st Floor,
Community Centre,
Basant Lok,
Vasant Vihar,
New Delhi – 110 057



### Bengaluru

No. 2, 3rd Floor,
Prestige
Emerald,
Lavelle Road,
Bengaluru – 560 001



### Hyderabad

No. 25 & 42, 3rd Floor,
Lumbini Avenue,
Near Preston Prime Mall
Main Road, Gachibowli,
Hyderabad – 500 032



### Pune

No. 7/352 1st Floor,
Elbee House,
Boat Club Road,
Sangamvadi,
Pune – 411 001



### Ahmedabad

No. 409, 4th Floor,
Venus Amadeus,
Near Jodhpur Cross Road,
Satellite,
Ahmedabad – 380 015



### Kolkata

No. 9A-1 & 9B-1,
9th Floor,
No. 95A,
Park Street,
Kolkata – 700 016



### Kochi

No.1285 F1, Ground floor,
The Quadrant, MP Pylee Road,
Jawahar Nagar Avenue,
Kadavanthra P O,
Ernakulam – 682 020



### Thiruvananthapuram

2nd Floor,
Mankulangara Tower,
Kuravankonam,
Pattom P.O.,
Trivandrum – 695 004



### Lucknow

Unit No.6, 3rd Floor
Marigold Building,
Sapru Marg Shahnajaf Road,
Hazratfang,
Lucknow – 226 001



### Kanpur

Unit No 205, 2nd Floor,
Imperial Square,
16/105,
MG Road,
Kanpur – 208 001



**Spark Global PWM Private Limited**
Unit number- GV-00-04-03-BC-24, Gate Village Building
04, Dubai International Financial Centre (DIFC), Dubai, UAE